title: [The practice guideline 'Neuraxis blockade and anticoagulation'].
abstract: In a patient with a coagulation disorder, the administration of a local anaesthetic by means of a needle or via the insertion of a catheter into the epidural space or spinal cavity may lead to bleeding and haematoma formation, with a danger of pressure on the spinal cord or nerve roots. Employing the method of the Dutch Institute for Healthcare (CBO) for the development of practice guidelines, a working group of anaesthesiologists, a haematologist and a hospital chemist have drawn up recommendations for neuraxis blockade in combination with anticoagulant therapy. In patients with a clinically acquired tendency toward increased bleeding, the management is highly dependent on the cause of the bleeding tendency. If the patient uses acetylsalicylic acid or clopidogrel, the medication must be withdrawn at least 10 days before neuraxis blockade is started. Therapy with glycoprotein-IIb/IIIa-receptor antagonists is an absolute contra-indication for neuraxis blockade. In patients who are using coumarin derivatives, neuraxis blockade results in an increased risk of a neuraxial haematoma. The coumarin derivative should then be withdrawn and replaced by a different form of anticoagulation. The use of low-molecular-weight heparin at the usual prophylactic dosage is not a contra-indication for neuraxis blockade and the risk of a neuraxial haematoma following neuraxis blockade is also not increased significantly by the subcutaneous administration of unfractionated heparin.
authors.affiliation: VU Medisch Centrum, afd. Anesthesiologie, Amsterdam. cbo@cbo.nl
authors.forename: J J
authors.initials: JJ
authors.lastname: De Lange
authors.forename: J W
authors.initials: JW
authors.lastname: Van Kleef
authors.forename: J J E
authors.initials: JJ
authors.lastname: Van Everdingen
mesh_terms: D000775:Anesthesia, Spinal / Q000009:adverse effects*; D000925:Anticoagulants / Q000009:adverse effects*; D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000503:physiopathology; D000075202:Contraindications; D006406:Hematoma / Q000139:chemically induced; D006801:Humans; D009407:Nerve Block / Q000009:adverse effects*; D017410:Practice Guidelines as Topic; D012307:Risk Factors
chemical_list: D000925:Anticoagulants
vernacular_title: Richtlijn 'Neuraxisblokkade en antistolling'.